Upper Tract Urothelial Carcinoma

FGFR Inhibition Provides Significant Activity in Patients With UTUC, FGFR3 Alterations
Fibroblast growth factor receptor 3 (FGFR3) is the most common mutation in urothelial carcinoma (UTUC), found in 54 to 92% of diagnosed patients. A recent phase 1b trial by Surena F. Matin, MD, and colleagues analyzed the effects of FGFR inhibitor infigratinib in localized UTUC. Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations. ...
Advertisement

Latest News

Advertisement

Roundtable Discussions

Urothelial Cancer Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Section Editor

Advertisement
Get the latest UTUC research straight to your inbox.